Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care

TOKYO, Aug 9, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a capital and business alliance agreement to collaborate in dementia and other areas, with the aim of helping reduce the burden of medical and nursing care for people living in Japan’s […]

Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022

TOKYO, Jul 26, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co. Ltd announced today that the company will present research from its Alzheimer’s disease (AD) pipeline, including new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild […]

Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business

TOKYO, Apr 1, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party […]

Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen

TOKYO, Mar 15, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer’s disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits […]

Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments

CAMBRIDGE, Mass., and TOKYO, Mar 15, 2022 – (JCN Newswire via SEAPRWire.com) – Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). Effective as of January 1, 2023, Eisai will receive a tiered […]

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

TOKYO, Mar 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401). The lecanemab […]

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

TOKYO, Jan 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV). H3B-8800 (Roivant’s Development Code: RVT-2001) is […]

Eisai and Digital Garage, Inc. Jointly Launch “Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)”

TOKYO, Nov 4, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it launches the “Open Network Lab BioHealth Dementia Innovation Challenge (Onlab Bio Dementia)”, a collaborative cultivation program jointly implemented with Digital Garage, Inc., with the aim of contributing to solving issues related to dementia and starts recruiting startups for […]

Eisai to Join The Global Environmental Initiative “RE100”

TOKYO, Sep 14, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has joined “RE100”, the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity. RE100 is an initiative committed to shifting the electricity used in business activities to 100% renewable energy […]

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries

TOKYO, Aug 31, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states: […]

Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate

Tokyo and New York, Jun 18, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines […]

Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma

TOKYO, Jun 15, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma. Zonegran is an antiepileptic drug (AED) originally created by Dainippon […]

KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries

TOKYO, Mar 31, 2021 – (JCN Newswire via SEAPRWire.com) – KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, […]

Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan

TOKYO, Nov 18, 2020 – (JCN Newswire) – Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, JAK (Janus kinase) inhibitor that preferentially inhibits JAK1, will be launched in Japan on November 18 for the treatment of rheumatoid arthritis (RA), with […]

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

TOKYO, Oct 26, 2020 – (JCN Newswire) – Eisai Co., Ltd. and Cogstate, Ltd. announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the “Cogstate Brief BatteryTM” (CBB) for use in healthcare and […]